4.6 Article

Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience

Journal

MAYO CLINIC PROCEEDINGS
Volume 85, Issue 10, Pages 905-912

Publisher

ELSEVIER SCIENCE INC
DOI: 10.4065/mcp.2010.0159

Keywords

-

Ask authors/readers for more resources

OBJECTIVE: To determine clinical features, natural history, and outcome of a well-defined cohort of 25 consecutive patients with Idiopathic systemic capillary leak syndrome (SCLS) evaluated at a tertiary care center. PATIENTS AND METHODS: Records of patients diagnosed as having SCLS from November 1, 1981, through April 30, 2008, were reviewed. Descriptive statistics were used to analyze patient demographics, clinical features, complications, and therapeutic interventions. RESULTS: Of the 34 patients whose records were reviewed, 25 fulfilled all diagnostic criteria for SCLS. The median age at diagnosis of SCLS was 44 years. Median follow-up of surviving patients was 4.9 years, and median time to diagnosis from symptom onset was 1.1 years (interquartile range, 0.5-4.1 years). Flullke illness or myalgia was reported by 14 patients (56%) at onset of an acute attack of SCLS, and rhabdomyolysis developed In 9 patients (36%). Patients with a greater decrease in albumin level had a higher likelihood of developing rhabdomyolysis (P=.03). Monoclonal gammopathy, predominantly of the IgG-kappa type, was found in 19 patients (76%). The progression rate to multiple myeloma was 0.7% per person-year of follow-up. The overall response rate to the different therapies was 76%, and 24% of patients sustained durable (>2 years) complete remission. The estimated 5-year overall survival rate was 76% (95% confidence interval, 59%-97%). CONCLUSION: Systemic capillary leak syndrome, a rare disease that occurs in those of middle age, Is usually diagnosed after a considerable delay from onset of symptoms. The degree of albumin decrement during an attack correlates with development of rhabdomyolysis. A reduction in the frequency and/or the severity of attacks was seen In nearly three-fourths of patients who were offered empirical therapies. The rate of progression to multiple myeloma appears to be comparable to that of monoclonal gammopathy of undetermined significance. Mayo Clin Proc. 2010;85(10):905-912

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Prognostic significance of acquired 1q22 gain in multiple myeloma

Hadiyah Y. Audil, Joselle M. Cook, Patricia T. Greipp, Prashant Kapoor, Linda B. Baughn, Angela Dispenzieri, Morie A. Gertz, Francis K. Buadi, Martha Q. Lacy, David Dingli, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Eli Muchtar, Mustaqeem Siddiqui, Wilson Gonsalves, Yi Lisa Hwa, Nelson Leung, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Robert A. Kyle, Rhett P. Ketterling, S. Vincent Rajkumar, Shaji K. Kumar

Summary: Acquisition of 1q22 gain in multiple myeloma patients is associated with reduced overall survival. Presence of high-risk FISH abnormalities at baseline increases the risk of acquiring 1q22 gain.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Hematology

Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia

Zaid H. Abdel Rahman, Ricardo D. Parrondo, Michael G. Heckman, Mikolaj Wieczorek, Kevin C. Miller, Hassan Alkhateeb, Lisa Z. Sproat, Hemant Murthy, William J. Hogan, Mohamed A. Kharfan-Dabaja, Jess F. Peterson, Linda B. Baughn, Nicole Hoppman, Mark R. Litzow, Rhett P. Ketterling, Patricia T. Greipp, James M. Foran

Summary: Patients with therapy-related acute lymphoblastic leukaemia (tr-ALL) differed significantly from de novo ALL patients in terms of age, gender, cytogenetic abnormalities, etc. Patients with tr-ALL were less likely to achieve complete remission, but had similar overall survival rates after diagnosis and allogeneic hematopoietic cell transplantation.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Pathology

Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group

Rashmi Kanagal-Shamanna, Attilio Orazi, Robert P. Hasserjian, Daniel A. Arber, Kaaren Reichard, Eric D. Hsi, Adam Bagg, Heesun Joyce Rogers, Julia Geyer, Faezeh Darbaniyan, Kim-Anh Do, Kyle M. Devins, Olga Pozdnyakova, Tracy George, Paola Dal Cin, Patricia T. Greipp, Mark J. Routbort, Keyur Patel, Guillermo Garcia-Manero, Srdan Verstovsek, L. Jeffrey Medeiros, Sa A. Wang, Carlos Bueso-Ramos

Summary: The study revealed that patients with MDS/MPN-i(17q) were typically younger with lower platelet and neutrophil counts, commonly displayed bilobed neutrophils and had a higher mutation frequency. These patients had a poorer prognosis and shorter overall survival compared to those without i(17q).

MODERN PATHOLOGY (2022)

Correction Pathology

Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group (Nov, 10.1038/s41379-021-00961-0, 2021)

Rashmi Kanagal-Shamanna, Attilio Orazi, Robert P. Hasserjian, Daniel A. Arber, Kaaren Reichard, Eric D. Hsi, Adam Bagg, Heesun Joyce Rogers, Julia Geyer, Faezeh Darbaniyan, Kim-Anh Do, Kyle M. Devins, Olga Pozdnyakova, Tracy I. George, Paola Dal Cin, Patricia T. Greipp, Mark J. Routbort, Keyur Patel, Guillermo Garcia-Manero, Srdan Verstovsek, L. Jeffrey Medeiros, Sa A. Wang, Carlos Bueso-Ramos

MODERN PATHOLOGY (2022)

Article Oncology

Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions

Alaa Koleilat, Patrick W. McGarrah, Horatiu Olteanu, Daniel L. Van Dyke, James B. Smadbeck, Sarah H. Johnson, George Vasmatzis, Nicole L. Hoppman, Xinjie Xu, Rhett P. Ketterling, Patricia T. Greipp, Linda B. Baughn, Mrinal S. Patnaik, Jess F. Peterson

Summary: This case study describes a 60-year-old male patient with AML carrying a rare t(4;12)(q12;p13) chromosomal abnormality. Through conventional chromosome studies and Mate-pair sequencing, the rearrangement of ETV6 gene was confirmed, excluding the involvement of the PDGFRA gene region and influencing the patient's medical management decisions.

CANCER GENETICS (2022)

Article Ophthalmology

BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers

Cristiane M. Lda, Jose Pulido, Patricia T. Greipp, Joaquin J. Garcia, Timothy W. Olsen, Lauren Dalvin, Diva Regina Salomao

Summary: BAP1 immunostaining in biopsies shows strong correlation with subsequent enucleations and well-established prognostic markers in uveal melanoma, indicating it as a potential additional prognostic tool for UM biopsies.

OCULAR ONCOLOGY AND PATHOLOGY (2022)

Article Hematology

Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms

Mithun Vinod Shah, Rakchha Chhetri, Ruchita Dholakia, Chung H. Kok, Naseema Gangat, Hassan B. Alkhateeb, Aref Al-Kali, Mrinal M. Patnaik, Anmol Baranwal, Patricia T. Greipp, Rong He, Kebede H. Begna, Ing Soo Tiong, Andrew H. Wei, Devendra Hiwase

Summary: Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a potential treatment option for acute myeloid leukemia, but its effectiveness in t-MN has not been extensively studied. A retrospective analysis of 378 t-MN patients revealed that the upfront use of venetoclax with other therapies improved survival, although progression-free survival (PFS) and overall survival (OS) remained poor. Therefore, further research on venetoclax should be conducted in all t-MN phenotypes.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Oncology

Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group

Alaa Koleilat, James B. Smadbeck, Cinthya J. Zepeda-Mendoza, Cynthia M. Williamson, Beth A. Pitel, Crystal L. Golden, Xinjie Xu, Patricia T. Greipp, Rhett P. Ketterling, Nicole L. Hoppman, Jess F. Peterson, Christine J. Harrison, Yassmine M. N. Akkari, Karen D. Tsuchiya, Mary Shago, Linda B. Baughn

Summary: In acute lymphoblastic leukemia, intrachromosomal amplification of chromosome 21 (iAMP21-ALL) is a common high-risk cytogenetic abnormality, and accurate identification is crucial for clinical management. The current method of identification, fluorescence in situ hybridization (FISH), has a risk of misidentification. The use of chromosomal microarray can overcome this risk effectively.

GENES CHROMOSOMES & CANCER (2022)

Letter Hematology

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Devendra Hiwase, Christopher Hahn, Elizabeth Ngoc Hoa Tran, Rakchha Chhetri, Anmol Baranwal, Aref Al-Kali, Kirsty Sharplin, Dariusz Ladon, Rachel Hollins, Patricia Greipp, Monika Kutyna, Hassan Alkhateeb, Talha Badar, Paul Wang, David M. Ross, Deepak Singhal, Naranie Shanmuganathan, Peter Bardy, Ashanka Beligaswatte, David Yeung, Mark R. Litzow, Abhishek Mangaonkar, Pratyush Giri, Cindy Lee, Angie Yong, Noemi Horvath, Nimit Singhal, Raghu Gowda, William Hogan, Naseema Gangat, Mrinal Patnaik, Kebede Begna, Ing S. Tiong, Andrew Wei, Sharad Kumar, Anna Brown, Hamish Scott, Daniel Thomas, Chung H. Kok, Ayalew Tefferi, Mithun Vinod Shah

BLOOD (2023)

Letter Hematology

Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience

Bahga Katamesh, Ahmad Nanaa, Rong He, David Viswanatha, Phuong Nguyen, Patricia Greipp, Kurt Bessonen, Naseema Gangat, Kebede Begna, Abhishek Mangaonkar, Mrinal Patnaik, William J. Hogan, Ayalew Tefferi, Mark Litzow, Mithun Vinod Shah, Cecilia Arana Yi, James Foran, Talha Badar, Hassan B. Alkhateeb, Aref Al-Kali

BLOOD ADVANCES (2023)

Letter Oncology

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome

Aref Al-Kali, Ahmad Nanaa, David Viswanatha, Rong He, Phuong Nguyen, Dragan Jevremovic, James M. Foran, Cecelia Arana Yi, Patricia T. Greipp, Naseema Gangat, Mrinal Patnaik, Ayalew Tefferi, Mark R. Litzow, Abhishek A. Mangaonkar, Mithun Vinod Shah, Talha Badar, Hassan B. Alkhateeb

BLOOD CANCER JOURNAL (2023)

Article Oncology

Conditional survival in multiple myeloma and impact of prognostic factors over time

Nadine H. Abdallah, Alexandra N. Smith, Susan Geyer, Moritz Binder, Patricia T. Greipp, Prashant Kapoor, Angela Dispenzieri, Morie A. Gertz, Linda B. Baughn, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Yi L. Hwa, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar

Summary: This study aimed to estimate conditional survival (CS) at 1-8 years from diagnosis and investigate the impact of baseline prognostic factors on CS in multiple myeloma (MM) patients. A retrospective study including 2556 MM patients diagnosed between 2004 and 2019 was conducted. The findings revealed that age ≥65 and proteasome inhibitor+immunomodulatory-based induction were associated with decreased and increased survival, respectively, retained at 5 years. High-risk cytogenetic factors had a significant adverse impact at 1 and 3 years but not 5 years. Chromosome 17 abnormality was associated with decreased survival only at 1 year. Overall, the 5-year CS remained stable at 1-5 years from diagnosis among MM patients, and the prognostic impact of high-risk cytogenetic factors decreased with additional years survived.

BLOOD CANCER JOURNAL (2023)

Article Pathology

MDM2 Amplification Status in a Cohort of Well-Characterized Myxofibrosarcoma: A Clinicopathologic Analysis of 22 Tumors

Nooshin K. Dashti, Judith Jebastin Thangaiah, Troy Gliem, Darlene Knutson, Sara Kloft-Nelson, Susan M. Armstrong, Ahmed Bakhshwin, Patricia Greipp, Karen J. Fritchie

Summary: Myxofibrosarcomas (MFS) are slow-growing superficial masses in elderly patients. Diagnosis can be challenging, as they can be mistaken for dedifferentiated liposarcoma with myxoid features. MDM2 amplification rate in MFS is low, but some cases do show this genetic alteration. Pathologists should be aware of this to avoid misclassification. Further studies are needed to determine the prognostic value of the amplification status.

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2023)

Review Pathology

Incidental Detection of TFEB-Amplified Renal Cell Carcinoma by Colocated Gene Amplification of CCND3 (6p21): A Case Report and Review of the Literature

Federico Repetto, Deepika Sirohi, Patricia Greipp, Jonathon Mahlow

Summary: TFEB-amplified renal cell carcinoma is characterized by genomic amplification at the 6p21.1 locus and is important to accurately diagnose to determine prognosis and treatment options.

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2023)

Article Hematology

Mediastinal B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements

Jon L. Ocal, Andrew L. Feldman, Patricia T. Greipp, Lisa M. Rimsza

Summary: This case report of a 23-year-old female with PMBL-TH highlights the importance of immunohistochemistry, FISH, and genetic expression analysis in diagnosis, expanding the understanding of DH/TH in B-cell lymphomas.

JOURNAL OF HEMATOPATHOLOGY (2022)

No Data Available